Compare ENTX & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | CHMI |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | Israel | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 97.0M |
| IPO Year | 2015 | N/A |
| Metric | ENTX | CHMI |
|---|---|---|
| Price | $1.24 | $2.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.00 | $3.00 |
| AVG Volume (30 Days) | 162.1K | ★ 203.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.38% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $61.13 |
| P/E Ratio | ★ $4.76 | $139.30 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $2.17 |
| 52 Week High | $3.22 | $3.14 |
| Indicator | ENTX | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 44.97 |
| Support Level | $1.17 | $2.50 |
| Resistance Level | $1.39 | $2.76 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 41.94 | 63.33 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.